Nanovesicles can be bioengineered to target cancer cells and deliver treatments directly, according to research at Binghamton University, State University of New York.
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business – Biotech Investments
EQS-News: Heidelberg Pharma AG / Key word(s): Half Year Report Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business 11.07.2024 / 07:05